# A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors

> **NCT01204996** · PHASE1 · COMPLETED · sponsor: **Centocor, Inc.** · enrollment: 53 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection
- **DRUG:** CNTO888 + gemcitabine
- **DRUG:** CNTO888 + Paclitaxel and carboplatin
- **DRUG:** CNTO888 + docetaxel

## Key facts

- **NCT ID:** NCT01204996
- **Lead sponsor:** Centocor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** —
- **Final completion:** 2011-11
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2012-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01204996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01204996, "A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01204996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*